LANDSCAPE ASSESSMENT AND KEY HTA CONSIDERATIONS IN ALZHEIMER'S DISEASE

被引：0
|
作者：
Takyar, S. [1 ]
Kaur, S. [1 ]
Takyar, J. [1 ]
Dhawan, A. [1 ]
机构：
[1] Parexel Int, Mohali, India
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND81
引用
收藏
页码：S752 / S752
页数：1
相关论文
共 50 条
  • [1] AN EVALUATION OF HEALTH TECHNOLOGY ASSESSMENT (HTA) REQUIREMENTS FOR EMERGING THERAPIES IN ALZHEIMER'S DISEASE (AD)
    Hartl, K.
    Gulser, Sahbaz S.
    Spoorendonk, J. A.
    Jose, R.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S298 - S299
  • [2] WHAT ARE THE KEY DRIVERS FOR CHANGING HTA DECISIONS? EXAMPLE OF ALZHEIMER'S DISEASE TREATMENT IN GERMANY, FRANCE AND UK
    Ackermann, J.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A329 - A329
  • [3] Proteomics Landscape of Alzheimer's Disease
    Jain, Ankit P.
    Sathe, Gajanan
    [J]. PROTEOMES, 2021, 9 (01) : 1 - 18
  • [4] The epigenetic landscape of Alzheimer's disease
    Lord, Jenny
    Cruchaga, Carlos
    [J]. NATURE NEUROSCIENCE, 2014, 17 (09) : 1138 - 1140
  • [5] The epigenetic landscape of Alzheimer's disease
    Jenny Lord
    Carlos Cruchaga
    [J]. Nature Neuroscience, 2014, 17 : 1138 - 1140
  • [6] MicroRNA Landscape in Alzheimer's Disease
    Cogoni, Carlo
    Ruberti, Francesca
    Barbato, Christian
    [J]. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2015, 14 (02) : 168 - 175
  • [7] Proteomic landscape of Alzheimer's disease
    Peng, Junmin
    [J]. JOURNAL OF NEUROCHEMISTRY, 2022, 162 : 152 - 152
  • [8] Economic considerations in Alzheimer's disease
    Meek, PD
    McKeithan, EK
    Schumock, GT
    [J]. PHARMACOTHERAPY, 1998, 18 (02): : 68 - 73
  • [9] Considerations to the psychosomatics of Alzheimer's disease
    Richarz, B
    [J]. DYNAMISCHE PSYCHIATRIE, 1997, 30 (5-6): : 340 - 355
  • [10] MODELING DISEASE PROGRESSION IN ALZHEIMER'S DEMENTIA TO INFORM HTA (CEA)
    Green, C.
    Zhang, S.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A563 - A563
12345